ENVB
Enveric BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
EB-003 continues to accumulate preclinical and safety evidence, while the company reports progress toward IND-enabling work and first-in-human trials. Successful clinical entry would be a meaningful de-risking event for a roughly $4.8 million company [#SEC-8K-2026-05-15] [#PR-EARNINGS-2026-05-19].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Coverage is low, peers are loose, and recent positive news is primarily issuer-generated.
Momentum
97
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.25 · Bull $2.30 · Bear $0.55
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $120.00
Why
Momentum97 · Δ7d -
Value41 · Δ7d -0.1
Sentiment41 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
97
26% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
41
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 96.8 / Value 41.1 / Sentiment 41.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.93M
Beta
0.28
Shares Out
3.68M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.07
Rev YoY
-100.0%
EPS YoY
-92.6%
Gross Margin
+12.7%
Op Margin
-
Net Debt
-$4.68M
Current Ratio
11.67
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology